CN101715452A - 氮杂吲哚-吲哚偶联衍生物及其制备和用途 - Google Patents

氮杂吲哚-吲哚偶联衍生物及其制备和用途 Download PDF

Info

Publication number
CN101715452A
CN101715452A CN200880019011A CN200880019011A CN101715452A CN 101715452 A CN101715452 A CN 101715452A CN 200880019011 A CN200880019011 A CN 200880019011A CN 200880019011 A CN200880019011 A CN 200880019011A CN 101715452 A CN101715452 A CN 101715452A
Authority
CN
China
Prior art keywords
acid
group
compound
derivatives
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN200880019011A
Other languages
English (en)
Other versions
CN101715452B (zh
Inventor
程景才
姚其正
王朝晖
华维一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WUXI JC PHARMACAUTICAL TECHNOLOGY INC.
Original Assignee
程景才
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 程景才 filed Critical 程景才
Priority to CN2008800190117A priority Critical patent/CN101715452B/zh
Publication of CN101715452A publication Critical patent/CN101715452A/zh
Application granted granted Critical
Publication of CN101715452B publication Critical patent/CN101715452B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明提供了一类全新结构的氮杂吲哚-吲哚偶联衍生物。这类衍生物分子结构上的共同特点在于：都是由氮杂吲哚和吲哚双分子在不同的位置上偶联而成，形成大π共轭的杂环体系。这类衍生物通过多种机制抑制细胞的生长和增殖。本发明还涉及这类衍生物的制备方法、含所述衍生物的药物组合物和用途。本发明化合物的溶解性有所改善，生物利用度得以提高，从而增强了药物作用，降低了药物剂量及不良反应。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN2008800190117A 2007-06-08 2008-06-06 氮杂吲哚-吲哚偶联衍生物及其制备和用途 Active CN101715452B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2008800190117A CN101715452B (zh) 2007-06-08 2008-06-06 氮杂吲哚-吲哚偶联衍生物及其制备和用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2007100233478A CN101074229B (zh) 2007-06-08 2007-06-08 7-氮杂靛玉红和7-氮杂异靛蓝衍生物制备及其药学用途
CN200710023347.8 2007-06-08
CN2007100233478 2007-06-08
PCT/CN2008/071228 WO2008151558A1 (fr) 2007-06-08 2008-06-06 Dérivés couplés d'azaindole et d'indole, procédés de préparation et utilisations
CN2008800190117A CN101715452B (zh) 2007-06-08 2008-06-06 氮杂吲哚-吲哚偶联衍生物及其制备和用途

Publications (2)

Publication Number Publication Date
CN101715452A true CN101715452A (zh) 2010-05-26
CN101715452B CN101715452B (zh) 2012-10-10

Family

ID=38975520

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2007100233478A Active CN101074229B (zh) 2007-06-08 2007-06-08 7-氮杂靛玉红和7-氮杂异靛蓝衍生物制备及其药学用途
CN2008800190117A Active CN101715452B (zh) 2007-06-08 2008-06-06 氮杂吲哚-吲哚偶联衍生物及其制备和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2007100233478A Active CN101074229B (zh) 2007-06-08 2007-06-08 7-氮杂靛玉红和7-氮杂异靛蓝衍生物制备及其药学用途

Country Status (10)

Country Link
US (1) US8642765B2 (zh)
EP (1) EP2168964B1 (zh)
JP (1) JP5216083B2 (zh)
KR (1) KR101191851B1 (zh)
CN (2) CN101074229B (zh)
AT (1) ATE528308T1 (zh)
AU (1) AU2008261491B2 (zh)
CA (1) CA2692922C (zh)
IL (1) IL202600A (zh)
WO (1) WO2008151558A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030069692A (ko) * 2002-02-22 2003-08-27 신학기 아파타이트 결정을 갖는 경량골재의 제조방법
EP2199292A1 (en) 2008-12-22 2010-06-23 Technische Universität Kaiserlautern 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament
EP2379549B1 (en) 2008-12-22 2016-09-21 Eisenbrand, Gerhard 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament
CN101492448B (zh) * 2009-03-05 2012-09-19 上海交通大学 用于抗肿瘤药物的7＇-氮杂靛玉红类化合物
EP2691538A1 (en) * 2011-03-28 2014-02-05 Novartis AG Markers associated with cyclin-dependent kinase inhibitors
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
EP3597178A1 (en) * 2012-06-21 2020-01-22 Phosphorex Inc. Nanoparticles of indirubin, derivatives thereof and methods of making and using same
CN103145605A (zh) * 2013-02-27 2013-06-12 广东省微生物研究所 一种1-乙酰基-卤代吲哚基-3-乙酸酯的合成方法
CN103333161B (zh) 2013-05-28 2015-09-30 滁州市洛达生物科技有限公司 1’-氧代靛玉红的制备和用途
CN104817485B (zh) * 2015-05-18 2017-04-19 安徽师范大学 一种异靛衍生物及其制备方法
CN110683981A (zh) * 2019-09-05 2020-01-14 湖南恒泰生物医药有限公司 一种5-溴-4-氯-1-乙酰基-3-吲哚酚合成方法
CN114920728B (zh) * 2022-05-27 2023-10-20 中南大学 一种甲异靛衍生物及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061555A1 (en) * 1999-04-12 2000-10-19 Gerhard Eisenbrand Indigoid bisindole derivatives
US6566341B1 (en) * 2001-12-13 2003-05-20 Natrogen Therapeutics, Inc. Derivative of isoindigo, indigo and indirubin for the treatment of cancer
CA2469649C (en) * 2001-12-13 2011-05-03 Natrogen Therapeutics, Inc. Derivatives of isoindigo, indigo and indirubin and use in treating cancer
CN1199946C (zh) * 2002-10-29 2005-05-04 无锡杰西医药科技有限公司 一种特异性吲哚类化合物及制备方法与其在治疗和预防癌症等疾病中的应用
CN100515389C (zh) 2004-07-14 2009-07-22 无锡杰西医药科技有限公司 一种适用于难溶性药物的药用乳剂及其制备方法
CN1329376C (zh) 2005-09-19 2007-08-01 无锡杰西医药科技有限公司 一种n（1）－烃基－3′－肟基靛玉红衍生物（i）的制备方法及其医学应用
CN1840196A (zh) 2006-01-27 2006-10-04 无锡杰西医药科技有限公司 一种适用于难溶性药物的分散剂

Also Published As

Publication number Publication date
EP2168964A4 (en) 2010-08-25
JP5216083B2 (ja) 2013-06-19
JP2010529050A (ja) 2010-08-26
US8642765B2 (en) 2014-02-04
US20100137356A1 (en) 2010-06-03
CN101074229A (zh) 2007-11-21
EP2168964A1 (en) 2010-03-31
RU2010101144A (ru) 2011-07-20
ATE528308T1 (de) 2011-10-15
CA2692922C (en) 2013-11-19
KR101191851B1 (ko) 2012-10-16
CN101715452B (zh) 2012-10-10
KR20100031613A (ko) 2010-03-23
IL202600A (en) 2013-08-29
CA2692922A1 (en) 2008-12-18
AU2008261491B2 (en) 2012-01-19
EP2168964B1 (en) 2011-10-12
WO2008151558A1 (fr) 2008-12-18
IL202600A0 (en) 2010-06-30
CN101074229B (zh) 2010-09-01
AU2008261491A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
CN101715452B (zh) 氮杂吲哚-吲哚偶联衍生物及其制备和用途
CN108125944A (zh) 一种紫杉醇和cdks激酶抑制剂抗肿瘤联合用药物组合物
CN105461714B (zh) 并环类pi3k抑制剂
CN110981870B (zh) 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途
JP2006526580A (ja) ハルミン誘導体、これらの調製において使用する中間体、調製過程およびこれらの使用
CN105189486A (zh) 苯并呋喃酮与吲哚或氮杂吲哚偶合物及其制备与应用
WO2022199547A1 (zh) 一种7,9-二氢嘌呤衍生物及其制药用途
Yuan et al. Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination
Liu et al. Discovery of novel tacrine derivatives as potent antiproliferative agents with CDKs inhibitory property
CN106831812A (zh) 含联芳基酰胺结构的杂环并嘧啶或吡嗪类化合物及其应用
CN106565685A (zh) 微管蛋白抑制剂
CN106892922B (zh) 作为egfr抑制剂的5,8-二氢蝶啶-6,7-二酮衍生物及其应用
CN111018897A (zh) 喜树碱衍生物及其用途
CN103965175A (zh) 4-(取代苯氨基)喹唑啉类化合物、其制备方法及应用
EP3012248B1 (en) Substance having tyrosine kinase inhibitory activity and preparation method and use thereof
CN113527391B (zh) 一种梓醇衍生物及其制备方法和应用
CN114478549A (zh) 一种吡唑并[3,4-d]吡咯(啶)并[1,2-a]嘧啶酮亚芳基类衍生物及其用途
CN110650961B (zh) Parp抑制剂、其药物组合物、制备方法和应用
RU2486184C2 (ru) Производные азаиндола-индола, способы их изготовления и использования
CN112851679B (zh) 2，4，7-三取代嘧啶并吲哚化合物抗肿瘤作用
Fadda et al. Effect of New Thalidomide Analogs in Acute Kidney Injury on Rats
Nafie et al. Exploring pyrrolidinyl-spirooxindole natural products as promising platforms for the synthesis of novel spirooxindoles as EGFR/CDK2 inhibitors for halting breast cancer cells
CN108186663A (zh) 一种抗肿瘤联合用药物组合物
TW202317572A (zh) 雜環大環化合物及其醫藥用途
CN115073361A (zh) 一种松香二萜类化合物及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: JIEXI MEDICAL SCIENCE + TECHNOLOGY CO., LTD., WUXI

Free format text: FORMER OWNER: CHENG JINGCAI

Effective date: 20150204

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 214000 WUXI, JIANGSU PROVINCE TO: 214028 WUXI, JIANGSU PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20150204

Address after: 214028 Changjiang Road in Jiangsu province Wuxi City District No. 7 District No. 200 A of garden of science and technology

Patentee after: Jiexi Medical Science & Technology Co., Ltd., Wuxi City

Address before: 214000 Jiangsu city of Wuxi Province River Road No. 170

Patentee before: Cheng Jingcai

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 214028 No. 1232, two building, science and Technology Park, Wuxi New District, Wuxi, Jiangsu.

Patentee after: WUXI JC PHARMACAUTICAL TECHNOLOGY INC.

Address before: 214028 No. 200, block A, seat 7, science and Technology Park, Changjiang Road, New District, Wuxi, Jiangsu.

Patentee before: Jiexi Medical Science & Technology Co., Ltd., Wuxi City